Patients with chronic hepatic disease are about 600 to 800 million people in the world, and it is considered that 3 million people among them can be treated with cell therapy. Accordingly, it is expected that the scale of cell therapy market will likely reach KRW 1 trillion. In accordance with the National Center for Health Statistics, in the case of the U.S., the illness emerges in 300,000 patients every year, and 30,000 patients among them have intractable diseases leading to death.
In particular, 2,000 patients or more with acute and acute chronic hepatic failure die every year during the waiting period of transplantation. The frequency of developing a hepatic disease shows a growing tendency, and the number of patients is expected to be increased by 400,000 people or more within the next 10 years. Liver transplantation is the most effective solution among current treatment methods, and medical expenses incurred by this method range from millions to hundreds of millions of won. However, various problems are found in liver transplantation owing to a lack of donors, surgical complications, immunological side effects, etc.
The treatment of intractable diseases by inducing stem cell differentiation to functional ones is the most highlighted field in biotechnology. Recently, as the importance for the quality management of stem cells is being emphasized to use them as ingredients for regenerative medicine, several tasks such as the establishment of human embryonic stem cells, analysis of characteristics, maintenance, culture, and standardization through the establishment of a cell line bank are in progress around the world. To elevate the functionality of hepatic cells differentiated from stem cells, diverse methods for hepatic cell differentiation are being developed and, using these, studies for transplanting them into various illness models are in progress. Also, hepatic cells derived from stem cells are being utilized in toxicity study, food and drug screening, as well as HCV infection model.
Various studies to make functional cells for cell therapy is being conducted in the HY and Indang Center of Regenerative Medicine and Stem Cell Research.
And, by consistently discovering and educating researchers, this center gives an effort to the development of human resources enabled to lead liver disease studies in the future. A study for applying hepatic cells to humans after differentiating the induced pluripotent stem cells (iPSCs) and the mesenchymal stem cells (MSC) to hepatocyes